Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Transfer Cellavista Business to SynenTec

NEW YORK (GenomeWeb News) – Roche today said that it will transfer its Cellavista Systems business to SynenTec, a German firm that is the original inventor of the technology.

The move is part of Roche's ongoing restructuring of its Applied Science unit, which includes shuttering its NimbleGen microarray business. As reported last month by GenomeWeb Daily News sister publication In Sequence, Roche plans to shed its Cellavista and xCELLigence cellular analysis systems, while integrating the remainder of the cell analysis business with biochemical reagents as part of the restructuring.

The Cellavista Imaging System is used for the noninvasive measurement of cell expansion and for cellular applications in cell line development, cellular research, and drug discovery.

SynenTec will take over worldwide distribution of the systems and provide application support and service. Roche will remain the primary contact for support needs until SynenTec resumes full responsibility for the systems on June 1, 2013.

Further terms of the transfer were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.